Sandoz and EirGenix to market Herceptin biosimilar
01-05-2019
Lucarista / Shutterstock.com
Switzerland-based Novartis today, March 12, failed to convince the EU General Court that its ‘Smartsurface’ trademark should be registered for contact lenses.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novartis, EU General Court, trademark registration, EUIPO, contact lenses, medical devices, trademarks
